672 reports of this reaction
2.9% of all IRINOTECAN HYDROCHLORIDE reports
#6 most reported adverse reaction
DISEASE PROGRESSION is the #6 most commonly reported adverse reaction for IRINOTECAN HYDROCHLORIDE, manufactured by Pharmacia & Upjohn Company LLC. There are 672 FDA adverse event reports linking IRINOTECAN HYDROCHLORIDE to DISEASE PROGRESSION. This represents approximately 2.9% of all 23,035 adverse event reports for this drug.
Patients taking IRINOTECAN HYDROCHLORIDE who experience disease progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DISEASE PROGRESSION is a less commonly reported adverse event for IRINOTECAN HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to disease progression, the following adverse reactions have been reported for IRINOTECAN HYDROCHLORIDE:
The following drugs have also been linked to disease progression in FDA adverse event reports:
DISEASE PROGRESSION has been reported as an adverse event in 672 FDA reports for IRINOTECAN HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DISEASE PROGRESSION accounts for approximately 2.9% of all adverse event reports for IRINOTECAN HYDROCHLORIDE, making it a notable side effect.
If you experience disease progression while taking IRINOTECAN HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.